Omeros Stock

Omeros Gross Margin

Gross Margin of Omeros (OMER) as of Aug 11, 2026.

Gross Margin

0.00

Last updated:

Gross Margin of Omeros is 2026 0.00 . Gross Margin of Omeros was 2025 0.00 . It decreases by % lower compared to the previous year.

Omeros's gross margin stands at -1.5%, down from 98.3% several years earlier.

Access this data via the Eulerpool API

Omeros Stock analysis

What does Omeros do? Omeros Corp is a biopharmaceutical company based in Seattle, Washington, that focuses on the discovery, development, and commercialization of innovative therapies. The company has developed a wide range of products and technologies in various areas of the medical sector, including ophthalmology, immunology, oncology, and neurology. Omeros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Omeros stock

On Eulerpool you can find the complete historical development of Gross Margin Omeros since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Omeros with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Omeros

All Key Metrics — Omeros